HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Fox v. Lancaster

This article was originally published in The Rose Sheet

Executive Summary

All About Eve fragrance products will continue to be marketed by Lancaster Group Worldwide, following an amicable settlement between plaintiffs Twentieth Century Fox and Paramount and defendants, Lancaster Group et al., the parties stated jointly. Lancaster will turn over its trademarks for the fragrances to Fox. On April 1, the parties presented the court with a stipulation and order dismissing the case "with prejudice, without costs, attorneys' fees or expenses to any party hereto, and with no findings of fact or conclusions of law being made or having been made." The plaintiffs filed suit in Manhattan federal court against Lancaster, alleging Lancaster's worldwide registration of marks under a licensing agreement with Joop for Brave Heart and All About Eve personal care products infringed trademarks for films of the same name ("The Rose Sheet" July 28, 1997, p. 9)...

Latest Headlines
See All
UsernamePublicRestriction

Register

RS005309

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel